134 related articles for article (PubMed ID: 26774656)
21. A naked antisense oligonucleotide with phosphorothioate linkages is taken up intracellularly more efficiently but functions less effectively.
Takahashi M; Seki M; Nashimoto M
Biochem Biophys Res Commun; 2021 Oct; 573():140-144. PubMed ID: 34411896
[TBL] [Abstract][Full Text] [Related]
22. Antisense inhibition of human telomerase by phosphorothioate oligonucleotide-peptide conjugates.
Diala I; Murao S; Fujii M
Nucleic Acids Symp Ser (Oxf); 2008; (52):679-80. PubMed ID: 18776562
[TBL] [Abstract][Full Text] [Related]
23. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
[TBL] [Abstract][Full Text] [Related]
24. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain.
Koppelhus U; Shiraishi T; Zachar V; Pankratova S; Nielsen PE
Bioconjug Chem; 2008 Aug; 19(8):1526-34. PubMed ID: 18646838
[TBL] [Abstract][Full Text] [Related]
25. β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression.
Mochizuki S; Sakurai K
Bioorg Chem; 2010 Dec; 38(6):260-4. PubMed ID: 20673953
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
27. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide.
Bongartz JP; Aubertin AM; Milhaud PG; Lebleu B
Nucleic Acids Res; 1994 Nov; 22(22):4681-8. PubMed ID: 7984418
[TBL] [Abstract][Full Text] [Related]
28. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues.
Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ
Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.
Bilanges B; Stokoe D
Biochem J; 2005 Jun; 388(Pt 2):573-83. PubMed ID: 15656792
[TBL] [Abstract][Full Text] [Related]
30. Fragment-based solid-phase assembly of oligonucleotide conjugates with peptide and polyethylene glycol ligands.
Dirin M; Urban E; Noe CR; Winkler J
Eur J Med Chem; 2016 Oct; 121():132-142. PubMed ID: 27236069
[TBL] [Abstract][Full Text] [Related]
31. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
32. Antisense effects of DNA-peptide conjugates.
Kubo T; Bakalova R; Ohba H; Fujii M
Nucleic Acids Res Suppl; 2003; (3):179-80. PubMed ID: 14510439
[TBL] [Abstract][Full Text] [Related]
33. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
Kim SM; Chae MK; Lee C; Yim MS; Bang JK; Ryu EK
Amino Acids; 2014 Nov; 46(11):2595-603. PubMed ID: 25151148
[TBL] [Abstract][Full Text] [Related]
34. Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation.
Kubo T; Zhelev Z; Bakalova R; Ohba H; Doi K; Fujii M
Org Biomol Chem; 2005 Sep; 3(18):3257-9. PubMed ID: 16132084
[TBL] [Abstract][Full Text] [Related]
35. Thiol-Cyanobenzothiazole Ligation for the Efficient Preparation of Peptide-PNA Conjugates.
Patil NA; Karas JA; Turner BJ; Shabanpoor F
Bioconjug Chem; 2019 Mar; 30(3):793-799. PubMed ID: 30645945
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
37. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
[TBL] [Abstract][Full Text] [Related]
38. Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis.
Gong N; Teng X; Li J; Liang XJ
ACS Appl Mater Interfaces; 2019 Jan; 11(1):37-42. PubMed ID: 30548064
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
40. Concise postsynthetic preparation of oligonucleotide-oligopeptide conjugates through facile disulfide bond formation.
Dirin M; Urban E; Lachmann B; Noe CR; Winkler J
Future Med Chem; 2015; 7(13):1657-73. PubMed ID: 26381134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
